Damon Runyon News

View New Articles By

News

Honors and AwardsJune 1, 2017

Evan Walsh is an agent of the William Raveis Real Estate Company. In two short years he went from raising funds for the Raveis Ride + Walk to support cancer research, to becoming a patient himself with stage three muscle-invasive bladder cancer, to a cancer survivor. Evan delivered the following speech at a conference of fellow William Raveis agents.

Hello everyone. My name is Evan Walsh of The Walsh Team, and I am an agent in the Wellesley Office.

Every year thousands of people across the country shave their heads for charity in support of people battling cancer. Unfortunately, that is not why I stand here, bald, today. Three months ago I was diagnosed with stage three muscle-invasive bladder cancer. I have just completed a six week cycle of chemotherapy and on April 28th I will be going under the knife for robotic surgery, where they will remove my bladder and make me a beautiful new one using a section of my small intestines.

Honors and AwardsMay 26, 2017

Why I Joined the March For Science

Last month, Aaron D. Viny, MD, a Damon Runyon-William Raveis Charitable Fund Fellow at Memorial Sloan Kettering Cancer Center participated in the March for Science in New York City. Below he explains his unique motivation for marching, and why he read every word of President Trump’s Affordable Healthcare Act.

Last month my wife and I took our 21-month-old daughter to the March for Science. Irrespective of the tidal wave of political changes that have happened in the last 6 months, as parents, we found ourselves inspired by a Sarah Silverman stand-up comedy routine we saw several years ago.

“Don’t tell girls they can be anything they want when they grow up, because it would never have occurred to them that they couldn’t. It’s like saying, ‘Hey when you get in the shower I’m NOT going to read your diary.’ ‘Wait, are you going to read my diary?’ ‘No! I said I’m not going to read your diary. Now go take a shower!”

Honors and AwardsMay 23, 2017

Rushika Perera and Roberto Zoncu Interview

To make breakthroughs against cancer, we need scientists willing to break the mold and push science in new directions. That is the goal of our Damon Runyon-Rachleff Innovation Award. We seek the top emerging talent in cancer research and provide seed funding for their new ideas.

In 2015, we selected a new Innovator at UC Berkeley, Roberto Zoncu, followed the next year by one at UCSF, Rushika Perera. Little did we know that they were married to each other. As they tell it, rather than Match.com, they had “bench.com.” They met working side-by-side at a laboratory bench at Yale University, spent some time as a bi-coastal couple, and now are building their own labs across the bay from each other.

Honors and AwardsMay 8, 2017

What Scientists Learn from Cancer Patients

Damon Runyon Fellow Elise C. Jeffery, PhD, from the University of Texas Southwestern Medical Center

A few weeks ago I had the opportunity to attend a dinner with prospective donors at the beautiful new home of Damon Runyon Cancer Research Foundation board member Cindy Sulzberger in West Palm Beach, Florida. Cindy invited several of her friends to the gathering, and they were all eager to hear about the work of Damon Runyon scientists, and the goals of the foundation. As I described my work to the group during dinner, I was impressed by their interest in cancer research. They had a number of good questions such as, “Will we ever find a silver bullet cure?” and “How much progress could be made if we spent an amount equal to the defense budget on cancer research?” Although these questions have no easy answer, they reflect the thoughts of those in the community who have been affected by this disease.

New DiscoveriesMay 8, 2017

Damon Runyon scientists receive Pershing Square Sohn Prizes for Young Investigators in Cancer Research

Three Damon Runyon scientists received 2017 Pershing Square Sohn Prizes for Young Investigators in Cancer Research. Recipients receive $200,000 per year for up to three years and opportunities to present their work to scientific and business audiences, helping to bridge the gap between the academic and business communities. This year, three of the six awards were granted to Damon Runyon scientists:

Yimon Aye, PhD (Damon Runyon Fellow ’09 – ’12), Weil Cornell Medicine, New York

Daniel A. Heller, PhD (Damon Runyon Fellow ‘10 – ’12), Memorial Sloan Kettering Cancer Center, New York

Eirini P. Papapetrou, MD, PhD (Damon Runyon-Rachleff Innovator ’14 – ’17), Icahn School of Medicine at Mount Sinai, New York

New DiscoveriesMay 3, 2017

Mapping genetic changes that drive aggressive brain tumors

C. Ryan Miller, MD, PhD (Damon Runyon Clinical Investigator ’09-’12) of the UNC Lineberger Comprehensive Cancer Center, Chapel Hill, and colleagues, reported two studies on the genetics underlying brain tumors. The first study showed that mutations in MAPK and PI3K affect how cancer starts in glial cells, brain cells that provide support and insulation for neurons. These mutations triggered tumor initiation and produced increasingly dense low-grade gliomas that quickly progressed to aggressive and often deadly glioblastoma (GBM).

New DiscoveriesMay 2, 2017

New members of National Academy of Sciences elected

Election to the National Academy of Sciences is one of the highest honors that can be earned by a U.S. scientist. In recognition of their distinguished and continuing achievements in biomedical research, members of the Damon Runyon community of scientists were inducted this month:

Ardem Patapoutian, PhD (Damon Runyon Scholar ’03-‘05, Fellow ’96-‘99), Scripps Research Institute, La Jolla

Guillermina Lozano, PhD (Former Fellowship Award Committee Member), M.D. Anderson Cancer Center, Houston

Honors and AwardsMay 1, 2017

'Celebrating Scientists' during National Cancer Research Month

May is National Cancer Research Month and we are ‘Celebrating Scientists’ who are working to cure, treat and prevent this deadly disease. Throughout the month we will introduce you to some of the brilliant Damon Runyon scientists who are pursuing innovative cancer research.

Honors and AwardsApril 26, 2017

NIH Funding Imperative for Crucial Life-saving Research

The following Op Ed by Ralph J. DeBerardinis, MD, PhD, a Damon Runyon Clinical Investigator, appeared in the Philadelphia Inquirer on April 14, 2017

THE WHITE HOUSE recently proposed slashing support to the National Institutes of Health, the federal agency funding thousands of health-related research projects in the United States. I direct a clinic and research laboratory developing cures for cancer and childhood genetic diseases. My lab runs on NIH funds, and I'm writing to outline why these cuts will be disastrous for our long-term prospects for health.

Honors and AwardsApril 21, 2017

The Future of Cancer Challenge

By Peter J. Turnbaugh, Damon-Runyon Innovator

For our 70^th Anniversary Annual Report, we recently asked some of our current award recipients how cancer will be prevented, diagnosed, and/or treated differently in the future. What can a future cancer patient, say 10-20 years from now, expect to experience? Their responses were fascinating, and over the next few months we will share their visions for the future on this blog.

Cancer is notoriously hard to treat due to the severity of side effects and the high rate of relapse. While one patient may show a miraculous recovery, the next may show very little response or have an adverse drug outcome. Polymorphisms in the human genome are important, but they can fail to explain most of the observed variation in treatment outcomes. Far less attention has been paid to our “second genome”, the microbiome—comprising the trillions of microbes that thrive in and on the human body.